Trials / Not Yet Recruiting
Not Yet RecruitingNCT06412718
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 274 (estimated)
- Sponsor
- IRCCS Ospedale San Raffaele · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Accepted
Summary
The cross-sectional observational clinical study related to rare eye diseases is a multi-center study in which the hypothesis is that neurokinin 1 receptor and/or substance P expression is increased in REDs associated with inflammation/pain. Moreover, the following alternative targets are: VEGF, PAX6 and pro-inflammatory cytokine. The following procedures are performed specifically for the study: samples of blood, tear fluid and impression cytology. Precisely during the ophthalmological exam performed according to normal clinical practice (uncorrected visual acuity, best spectacle corrected visual acuity, corneal topography, corneal pachymetry and the slit lamp pictures) investigator's team collect the samples of blood, tear fluid and impression cytology to evaluate the goal of the study.
Conditions
- Rare Diseases
- Aniridia
- Neurotrophic Keratopathy
- Limbal Stem Cell Deficiency
- Ocular Graft-versus-host Disease
- Ocular Cicatricial Pemphigoid
- EEC Syndrome
- Corneal Neovascularization
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2025-04-01
- Completion
- 2026-04-01
- First posted
- 2024-05-14
- Last updated
- 2024-05-14
Source: ClinicalTrials.gov record NCT06412718. Inclusion in this directory is not an endorsement.